• Tenofovir vs Entecavir After HBV-Related HCC Resection: Surv

  2026-06-11

  A recent cohort study directly compared tenofovir disoproxil and entecavir in patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) undergoing curative liver resection. The findings indicate tenofovir was associated with improved long-term overall and recurrence-free survival, providing critical guidance for antiviral selection in this high-risk population.

• CX-4945 (Silmitasertib): Reliable CK2 Inhibition in Lab Assa

  2026-06-10

  This article addresses practical challenges in cell viability and cytotoxicity assays, illustrating how 'CX-4945 (Silmitasertib)' (SKU A8330) offers reproducible, data-driven solutions for CK2 inhibition workflows. Evidence-based protocol tips and real-world troubleshooting insights are highlighted to support experimental reliability for biomedical researchers and lab technicians.

• BMX-IN-1: Applied Workflows for BMX Kinase Inhibitor Researc

  2026-06-10

  BMX-IN-1 stands out as a highly selective, irreversible BMX kinase inhibitor, enabling precise interrogation of signaling pathways in cancer and host-pathogen models. This article translates recent mechanistic insights into stepwise protocols and troubleshooting strategies, empowering researchers to harness BMX-IN-1’s unique properties for advanced cellular and infection studies.

• JC-1 Mitochondrial Membrane Potential Assay Kit: Precision i

  2026-06-09

  The JC-1 Mitochondrial Membrane Potential Assay Kit enables sensitive, ratiometric analyses of mitochondrial function and cell apoptosis, empowering advanced drug mechanism studies and immunomodulation workflows. Its robust protocol, built-in positive control, and high-throughput capability make it indispensable for dissecting mitochondrial health in both basic and translational research.

• Fosinopril Sodium: Advanced ACE Inhibition in Cardio-Renal M

  2026-06-09

  Explore how Fosinopril sodium, a next-generation ACE inhibitor, enables precise modulation of cardiovascular and renal pathways in disease models. This article delivers novel protocol guidance, mechanistic insight, and practical assay recommendations for hypertension research.

• Nanoparticle Uptake in Corneal Cells: Role of Physicochemica

  2026-06-08

  This study delineates how nanoparticle size and surface chemistry direct the internalization mechanisms in human corneal epithelial cells. The findings reveal that energy-dependent endocytosis, especially macropinocytosis and caveolae-mediated uptake, are dominant, informing the rational design of ocular drug delivery systems with improved bioavailability.

• CDK9 Inhibitor (A3294): Technical Guidance and Best Practice

  2026-06-08

  CDK9 inhibitor (A3294) enables selective inhibition of cyclin dependent kinase 9, supporting research focused on transcription elongation and HIV-1 propagation while minimizing off-target and cytotoxic effects. It should not be used for broad-spectrum CDK inhibition or workflows requiring long-term storage of working solutions.

• Calpain Inhibitor I, ALLN: Technical Guide for Apoptosis & I

  2026-06-07

  Calpain Inhibitor I, ALLN is a potent, selective inhibitor of calpain and cathepsin proteases, optimized for apoptosis assays and ischemia-reperfusion injury models. It addresses the need for reproducible, targeted protease inhibition in both cell-based and in vivo workflows. This compound is not intended for diagnostic or clinical use, and researchers should be mindful of its solubility and storage requirements for optimal results.

• Fulvestrant (ICI 182,780): Mechanisms and Research Workflows

  2026-06-06

  Fulvestrant (ICI 182,780) is a high-affinity estrogen receptor antagonist that induces ERα degradation, disrupts ER signaling, and sensitizes ER-positive breast cancer cells to chemotherapy. APExBIO’s formulation is widely used in advanced breast cancer research and immune modulation studies. This article provides atomic, verifiable insights and workflow guidance for optimal use.

• AM 281 (SKU B6603): Optimizing CB1 Antagonist Use in Neuroph

  2026-06-05

  This article provides scenario-driven, evidence-based guidance for biomedical researchers and lab technicians employing AM 281 (SKU B6603) in neuropharmacological assays. Addressing real workflow challenges—from assay reproducibility to reliable vendor selection—it synthesizes current literature and practical lab experience to demonstrate how AM 281 enables precise, reproducible interrogation of the CB1 cannabinoid receptor axis.

• Anisomycin: Potent JNK Agonist for Apoptosis and Memory Mode

  2026-06-05

  Anisomycin is a potent JNK agonist that activates apoptosis and modulates cellular stress responses. Its utility in both cancer research and studies of synaptic plasticity is supported by robust evidence. This article summarizes its mechanism, benchmarks, and practical workflow integration.

• Golgi-Tracker Green: Live-Cell Golgi Labeling Optimized for

  2026-06-04

  Golgi-Tracker Green, a BODIPY FL-labeled C5-ceramide probe from APExBIO, sets a new standard for live-cell Golgi apparatus labeling, offering unmatched photostability and membrane specificity. This article details workflow enhancements, advanced troubleshooting, and translational tips to empower lipid transport and sphingolipid metabolism analysis.

• Resibufogenin Inhibits NLRP3 Inflammasome to Reduce Atherosc

  2026-06-04

  This study demonstrates that resibufogenin (RBG) effectively inhibits NLRP3 inflammasome assembly, leading to reduced inflammation and atherosclerotic plaque formation in ApoE-/- mice. The findings highlight a novel mechanism for RBG and suggest its therapeutic potential in managing atherosclerosis and related inflammatory diseases.

• Levofloxacin: Mechanistic Insights and Assay Optimization in

  2026-06-03

  Discover how Levofloxacin, a synthetic fluoroquinolone antibiotic, shapes advanced antibacterial and bone biology assays by linking molecular mechanisms to practical workflow optimization. Uncover novel strategies for precision experimental design and cross-domain research.

• Simvastatin (Zocor): Novel Insights into Autophagy and Cance

  2026-06-03

  Explore how Simvastatin (Zocor) extends beyond cholesterol research, revealing autophagy induction and anti-cancer mechanisms. This article delivers unique, protocol-focused guidance for leveraging Simvastatin’s multifaceted roles in advanced biomedical research.

418 records 6/28 page Previous Next First page 上5页 678910 下5页 Last page